Watch this on-demand presentation about imaging data quality and how the advancements in AI and machine learning help track the quality of images, assess issues early, and track trends in your quality steps.
Read More
Our experts explore the medical, operational, imaging, and regulatory considerations for radiopharmaceutical dosimetry.
Read More
In this new whitepaper, experts from Medpace and Medidata discuss the recent advances in artificial intelligence and machine learning and the benefits of using this technology to boost reliability and speed of imaging analysis in clinical trials.
Read More
This brand new infographic explores the different types of imaging techniques, their advantages, limitations, and how they can be successfully implemented in clinical trials.
Read More
The International Liver Congress (ILC) took place digitally this year, but it was worth logging in to keep up-to-date on the novel findings in imaging technology in non-alcoholic fatty liver disease (NAFLD) and steato-hepatitis (NASH) domains. See what you missed at the event.
Read More
Medpace is excited to welcome Kristi Clark, PhD, to Medpace Core Laboratories. Dr. Clark is trained in neuroscience and joins Medpace as a Project Manager in the Medpace Imaging Core Laboratory. We asked Dr. Clark about her experience and what drew her to Medpace.
Read More
In a new article, experts from Medpace’s radiation oncology, imaging, regulatory, and operational teams discuss the growing space of radiopharmaceutical development.
Read More
Medpace is excited to announce an agreement with Medidata to integrate imaging and clinical data into a single platform. The MCL-Medidata partnership offers Sponsors seamless integration of quantitative imaging endpoints with clinical imaging trial management needed to meet modern regulatory requirements.
Read More
Medpace Core Laboratories successfully completed a comprehensive inspection by the FDA on a late phase, registrational, oncology trial. The inspection concluded with no major or minor findings, reflecting the high quality and systematic execution of the trial by MCL.
Read More
As more agents approach the clinic, it is imperative for researchers to consider the design and conduct of immuno-oncology clinical trials. Given the diversity of agents in this newly tapped field, researchers may encounter unique challenges for site selection, patient selection, biomarker selection and imaging for assessing patient responses.
Read More